Significados de evasion or tolerance of host immune response en inglés

Tumor immune escape has been a major problem for developing effective immunotherapy.

Augmenting immune surveillance and suppressing immune escape are crucial in tumor immunotherapy.

Recent evidence has revealed that oncogenic mutations may confer immune escape.

The HPV protein responsible for inducing this immune escape has not been determined.

Secondly, graft failure and the immune escape of extramedullary plasmocytoma have been reported.

This finding led us to hypothesize that a conserved structural basis of antigenic escape from anti-AMA-1 exists.

Here, we describe the evolution of antigenic escape variants in a rhesus macaque that developed unusually high neutralizing antibody titers to SIVmac239.

By using an in vitro model of antigenic escape, the inhibitory contribution of 24 polymorphic sites of the 3D7 AMA-1 vaccine was determined.

This is particularly true for HIV, which has developed numerous immune evasion mechanisms.

For example, tumor cells have been shown to develop active immune evasion mechanisms.

Therefore, viruses have developed mechanisms to target TRIMs for immune evasion.

Exhaustion and suppression of antiviral immune responses can result in viral immune evasion.

This immune evasion mechanism imposes limitations on antibody-based vaccination and convalescent serum therapy.